In particular, we have found that CD24 silencing could prevent functional inactivation of p53 by both somatic mutation and viral oncogenes, and that TP53 mutated at a higher rate among glioma and prostate cancer samples with higher CD24 mRNA levels (Wang et al., 2015). This evidence concerns the gene CD24 and prostate carcinoma.